Lightnews — Scholar-powered news

Tempus AI

@tempusai.bsky.social

Tempus is advancing data-driven precision medicine through the practical application of AI in healthcare. It’s About Time.
www.tempus.com

Posts Replies Media Videos

Reposted by Tempus AI

Yale Cancer Center

@yalecancer.bsky.social

Dr. Frederick Wilson + colleagues have identified RASGRF1/2 fusions across a variety of tumor types, gaining insight on incidence, structural diversity, + tissue distribution of this distinct fusion class.
🔗 www.nature.com/articles/s41... @tempusai.bsky.social

Genetic and oncogenic features of RASGRF fusions - npj Precision Oncology

npj Precision Oncology - Genetic and oncogenic features of RASGRF fusions

nature.com

July 8, 2025 at 12:02 PM

Reposted by Tempus AI

The Cancer Letter

@cancerletter.com

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing (@tempusai.bsky.social‬)
https://cancerletter.com/drugs-and-targets/20250711_11a/

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing - The Cancer Letter

Personalis Inc. and Tempus AI Inc. have expanded and extended their strategic collaboration, adding a new indication, colorectal cancer, to the existing, exclusive commercialization agreement. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are […]

cancerletter.com

July 13, 2025 at 2:00 PM

Reposted by Tempus AI

The Cancer Letter

@cancerletter.com

"This approach not only increases the likelihood of trial success, but also reduces the financial burden of conducting studies," write Eric Lefkofsky and Norman E. Sharpless
cancerletter.com/trials-and-t...

Unlocking the future of precision medicine: The untapped power of RNA - The Cancer Letter

True innovation in healthcare requires us to look beyond the obvious. For years, DNA sequencing has been the key pillar of precision medicine, offering insights into disease predispositions, mechanism...

cancerletter.com

May 28, 2025 at 2:45 PM

Tempus AI

@tempusai.bsky.social

Looking forward to seeing you at #ASCO25! Attend our Industry Expert Theater with Kate Sasser, PhD, Ezra Cohen, MD, and Halla Nimeiri, MD, to discover how we are redefining precision oncology at scale—where our tests fuel smarter decisions and data advances care. Find more info: tempus.co/3S7WDYp

May 21, 2025 at 9:18 PM

Tempus AI

@tempusai.bsky.social

We’re excited to announce a collaboration to develop a companion diagnostic test with Verastem Oncology.

Our FDA-approved xT CDx assay is being leveraged as an investigational assay in Verastem’s global Phase 3 RAMP-301 clinical trial. Read more: tempus.co/3H3F9Kw

May 20, 2025 at 7:13 PM

Reposted by Tempus AI

Boehringer Ingelheim

@boehringerglobal.bsky.social

#NEWS: We are joining forces with @tempusai.bsky.social

By combining our experimental data with Tempus AI's real-world data on its AI-powered platform, we aim to pave the way for novel cancer treatments.

Learn more: bit.ly/43owlqa

#DataScience #Cancer #ResearchCollaboration

A young man shows a tablet screen to an older man. The headline says "Progressing cancer care." and on the bottom right "Life forward".

May 14, 2025 at 1:11 PM

Tempus AI

@tempusai.bsky.social

At #MIGlobal, Kate Sasser, PhD, our Chief Scientific Officer, participated in the "Accelerating a Healthier Future Through AI" panel." @milkeninstitute.org

Watch the full recording here: milkeninstitute.org/content-hub/...

May 9, 2025 at 4:39 PM

Tempus AI

@tempusai.bsky.social

We're on-site at #GU25! Stop by Booth #30 to meet with our team, learn more about our research in genitourinary cancers and explore our latest advancements in tech and #AI.

February 14, 2025 at 6:16 PM